Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CYBN NASDAQ:DRUG NASDAQ:KLRS NASDAQ:KYTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYBNCybin$7.52+0.8%$7.77$4.81▼$13.88$173.14M0.69284,497 shs222,450 shsDRUGBright Minds Biosciences$24.82+1.9%$28.28$0.94▼$79.02$174.73M-6.01823,129 shs12,647 shsKLRSKalaris Therapeutics$2.46+2.5%$0.00$2.28▼$24.15$46.00M0.4838,179 shs36,951 shsKYTXKyverna Therapeutics$4.07+6.5%$2.86$1.78▼$11.40$175.90M2.95389,274 shs551,287 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYBNCybin-0.13%-2.23%-10.66%+0.13%+1,921.68%DRUGBright Minds Biosciences-5.03%-8.90%-11.68%-23.90%+2,288.24%KLRSKalaris Therapeutics-8.05%-6.98%-9.09%+239,999,900.00%+239,999,900.00%KYTXKyverna Therapeutics-12.98%+35.46%+18.63%+108.74%-61.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYBNCybin2.4772 of 5 stars3.60.00.00.02.10.81.3DRUGBright Minds Biosciences2.4049 of 5 stars3.62.00.00.02.72.50.0KLRSKalaris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKYTXKyverna Therapeutics2.6437 of 5 stars3.62.00.00.03.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYBNCybin 3.25Buy$85.001,030.32% UpsideDRUGBright Minds Biosciences 3.13Buy$83.25235.41% UpsideKLRSKalaris Therapeutics 0.00N/AN/AN/AKYTXKyverna Therapeutics 3.14Buy$18.50354.55% UpsideCurrent Analyst Ratings BreakdownLatest KLRS, CYBN, DRUG, and KYTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025CYBNCybinCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$73.00 ➝ $70.007/2/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight5/27/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $5.005/21/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/13/2025DRUGBright Minds BiosciencesCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/13/2025CYBNCybinCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025DRUGBright Minds BiosciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/7/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYBNCybinN/AN/AN/AN/A$10.83 per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$0.92 per shareN/AKLRSKalaris TherapeuticsN/AN/AN/AN/A$22.47 per shareN/AKYTXKyverna TherapeuticsN/AN/AN/AN/A$6.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYBNCybin-$57.88M-$3.88N/AN/AN/AN/A-37.58%-36.59%N/ADRUGBright Minds Biosciences-$2.06M-$0.36N/AN/AN/AN/A-14.56%-14.29%8/13/2025 (Estimated)KLRSKalaris Therapeutics-$58.77MN/A0.00∞N/AN/A-62.08%-54.69%N/AKYTXKyverna Therapeutics-$127.48M-$3.38N/AN/AN/AN/A-51.66%-45.92%8/11/2025 (Estimated)Latest KLRS, CYBN, DRUG, and KYTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025N/ADRUGBright Minds Biosciences-$0.59N/AN/AN/AN/AN/A8/11/2025Q2 2025KYTXKyverna Therapeutics-$1.00N/AN/AN/AN/AN/A5/15/2025Q2 2025DRUGBright Minds Biosciences-$0.39-$0.29+$0.10-$0.29N/AN/A5/13/2025Q1 2025KYTXKyverna Therapeutics-$1.21-$1.03+$0.18-$1.03N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYBNCybinN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYBNCybinN/A24.2424.24DRUGBright Minds BiosciencesN/A126.01126.01KLRSKalaris TherapeuticsN/A14.3114.31KYTXKyverna TherapeuticsN/A7.447.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYBNCybin17.94%DRUGBright Minds Biosciences40.52%KLRSKalaris Therapeutics66.05%KYTXKyverna Therapeutics18.08%Insider OwnershipCompanyInsider OwnershipCYBNCybin15.00%DRUGBright Minds Biosciences42.66%KLRSKalaris Therapeutics74.99%KYTXKyverna Therapeutics22.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYBNCybin5023.02 million17.96 millionNot OptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableKLRSKalaris Therapeutics11018.70 million4.68 millionN/AKYTXKyverna Therapeutics9643.22 millionN/AOptionableKLRS, CYBN, DRUG, and KYTX HeadlinesRecent News About These CompaniesPeapod Lane Capital LLC Invests $765,000 in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)July 10, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Buy" from AnalystsJuly 10, 2025 | marketbeat.comKYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJuly 2, 2025 | globenewswire.comKyverna Therapeutics Names Marc Grasso Chief Financial OfficerJune 30, 2025 | marketwatch.comKyverna Therapeutics Announces Appointment of New Chief Financial OfficerJune 30, 2025 | finance.yahoo.comKyverna Therapeutics (NASDAQ:KYTX) Activity Grows on Nasdaq Composite, Russell 1000June 27, 2025 | kalkinemedia.comK3 Promising Penny Stocks With Market Caps Over $100MJune 10, 2025 | finance.yahoo.comKyverna Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | prnewswire.comHC Wainwright & Co. Upgrades Kyverna Therapeutics (KYTX)May 27, 2025 | msn.comKyverna Therapeutics: Buy Rating Backed by Promising Pipeline and Strong Financial PositionMay 27, 2025 | tipranks.comKyverna Shareholder Sues Over Kidney Therapy Trial Data Post IPOMay 15, 2025 | news.bloomberglaw.comNWith 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investorsMay 15, 2025 | finance.yahoo.comKYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmMay 15, 2025 | globenewswire.comKyverna Therapeutics Reports Q1 2025 Progress and OutlookMay 14, 2025 | tipranks.comKyverna lays off 16% of staff as autoimmune CAR-T plans pick up paceMay 14, 2025 | fiercebiotech.comFKyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | prnewswire.comWhy Kyverna Therapeutics, Inc.’s (KYTX) Stock Is Down 5.26%May 6, 2025 | aaii.comAWhy Kyverna Therapeutics, Inc.’s (KYTX) Stock Is Down 5.19%May 2, 2025 | aaii.comAWhy Kyverna Therapeutics, Inc.’s (KYTX) Stock Is Up 6.52%April 17, 2025 | aaii.comAWhy Kyverna Therapeutics, Inc.’s (KYTX) Stock Is Down 5.38%April 15, 2025 | aaii.comAKyverna Therapeutics price target lowered to $4 from $6 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeWhy Hims & Hers Is a Buy Below $35 After Its 16% PullbackBy Gabriel Osorio-Mazilli | July 3, 2025View Why Hims & Hers Is a Buy Below $35 After Its 16% PullbackNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?By Leo Miller | June 28, 2025View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?KLRS, CYBN, DRUG, and KYTX Company DescriptionsCybin NYSE:CYBN$7.52 +0.06 (+0.80%) Closing price 04:00 PM EasternExtended Trading$7.55 +0.03 (+0.40%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Bright Minds Biosciences NASDAQ:DRUG$24.82 +0.46 (+1.89%) Closing price 04:00 PM EasternExtended Trading$25.11 +0.29 (+1.17%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Kalaris Therapeutics NASDAQ:KLRS$2.46 +0.06 (+2.50%) As of 04:00 PM EasternAllovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Kyverna Therapeutics NASDAQ:KYTX$4.07 +0.25 (+6.54%) Closing price 04:00 PM EasternExtended Trading$3.94 -0.13 (-3.22%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
